close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Incyte Corporation - Common Stock (NQ:INCY)

105.55 -0.69 (-0.65%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
24 25 Next >
News headline image
7 Undervalued Biotech Stocks to Buy for Big-Time Returns ↗
The broader healthcare sector enjoys a powerfully relevant narrative. Undervalued biotech stocks makes the case even more attractive. 
Via InvestorPlace
News headline image
NASDAQ:INCY is not too expensive for the growth it is showing. ↗
In the world of growth stocks, INCYTE CORP (NASDAQ:INCY) shines as a value proposition. 
Via Chartmill
News headline image
For those who appreciate value investing, NASDAQ:INCY is a compelling option with its solid fundamentals. ↗
In a market where value is scarce, INCYTE CORP (NASDAQ:INCY) offers a refreshing opportunity with its solid fundamentals. 
Via Chartmill
News headline image
Analyst Expectations For Incyte's Future ↗
 
Via Benzinga
News headline image
Nasdaq 100, S&P 500 Close At Record Highs As Tech Stocks Reclaim Dominance: Thursday's Gainers & Losers ↗
The Nasdaq 100 index posted its fourth consecutive session in the green on Thursday, closing at 19,576 points and reaching all-time highs. 
Via Benzinga
Topics Stocks
News headline image
Despite its growth, NASDAQ:INCY remains within the realm of affordability. ↗
Don't overlook INCYTE CORP (NASDAQ:INCY)—a stock with solid growth prospects and a reasonable valuation. 
Via Chartmill
News headline image
9 Analysts Have This To Say About Incyte ↗
 
Via Benzinga
News headline image
Incyte Announces Final Results of Tender Offer
From Incyte Corporation
Via Business Wire
News headline image
Incyte Announces Preliminary Results of Tender Offer
From Incyte Corporation
Via Business Wire
News headline image
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Incyte
Via Business Wire
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
NASDAQ:INCY is showing decent growth, but is still valued reasonably. ↗
INCYTE CORP (NASDAQ:INCY) is not too expensive for the growth it is showing. 
Via Chartmill
News headline image
Peeling Back The Layers: Exploring Incyte Through Analyst Insights ↗
 
Via Benzinga
News headline image
Incyte Completes Acquisition of Escient Pharmaceuticals
From Incyte
Via Business Wire
News headline image
When you look at NASDAQ:INCY, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. ↗
INCYTE CORP (NASDAQ:INCY) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. 
Via Chartmill
News headline image
Hedge Funds Tweak Portfolios In Q1: Marvell, TD Synnex, AES Get More Love As Focus Shifts To AI ↗
Hedge funds are looking for high-return opportunities beyond the mega-cap tech giants preferring to focus on cyclical sectors and AI. 
Via Benzinga
News headline image
Incyte Expands Presence in Delaware through Acquisition of Two Downtown Wilmington Office Buildings
From Incyte
Via Business Wire
News headline image
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
News headline image
Incyte to Highlight Data From its Oncology Portfolio at the 2024 ASCO Annual Meeting and EHA2024 Congress
From Incyte
Via Business Wire
News headline image
Tech Stocks Inch Higher Ahead Of Key Inflation Data, GameStop Skyrockets, Tencent Fuels China Rally: What's Driving Markets Monday? ↗
Wall Street kicked off a data-heavy week on a mixed note as traders await key inflation updates and remarks from Fed Chair Jerome Powell in the coming days. 
Via Benzinga
Topics Economy
News headline image
GameStop, Squarespace, Incyte And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
Incyte Announces Intention to Buy Back up to $2.0 Billion of its Common Stock
From Incyte Corporation
Via Business Wire
News headline image
The 3 Best Biotech Stocks to Buy in May 2024 ↗
If you have the appetite for the risk inherent in the biotech sector, here are three biotech stocks to buy in May. 
Via InvestorPlace
News headline image
NASDAQ:INCY appears to be flying under the radar despite its strong fundamentals. ↗
INCYTE CORP (NASDAQ:INCY) is an undervalued gem with solid fundamentals. 
Via Chartmill
News headline image
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
News headline image
INCY Stock Earnings: Incyte Misses EPS, Misses Revenue for Q1 2024 ↗
INCY stock results show that Incyte missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs
From Incyte
Via Business Wire
News headline image
Don't overlook NASDAQ:INCY—a stock with solid growth prospects and a reasonable valuation. ↗
In the world of growth stocks, NASDAQ:INCY shines as a value proposition. 
Via Chartmill
News headline image
Incyte Should Consider Significant Stock Buyback And Prioritize R&D, Analyst Recommends ↗
Incyte acquires Escient Pharmaceuticals for $750 million, bolstering its pipeline. Cantor Fitzgerald initiates coverage with a Neutral rating, citing undervaluation concerns despite strong cash flow. 
Via Benzinga
News headline image
Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists
From Incyte and Escient Pharmaceuticals
Via Business Wire
< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
24 25 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today